rBet v 1: Phase IIb/III data

The double-blind, international Phase IIb/III VO59.08 trial in 483 adult patients showed that 12.5, 25 and 50 µg sublingual tablets of rBet v 1 met the primary endpoint of significantly reducing AASS ...